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Pyrrolepolyamide-2 -deoxyguanosine hybrids (Hybrid 2 and Hybrid 3) incorporating the 3-aminopropionyl or 3-aminopropyl
linker were designed and synthesized on the basis of previously reported results of a pyrrolepolyamide-adenosine hybrid (Hybrid
1). Evaluation of the DNA binding sequence selectivity of pyrrolepolyamide-2 -deoxyguanosine hybrids was performed by CD
spectral and Tm analyses. It was shown that Hybrid 3 possessed greater binding speciﬁcity than distamycin A, Hybrid 1 and
Hybrid 2.
1.Introduction
Organic compounds capable of controlling gene expression
may potentially be used as viable gene therapy agents. In
this regard, one of the most important requirements the
drug must possess is the ability to selectively distinguish
targetsequencesfromallothersequenceswithinthegenome.
The development of antisense or antigene drugs comprising
syntheticoligonucleotideshasbeeninvestigated[1].Further-
more, it was reported that pyrrolepolyamide molecules such
as distamycin A (Dst) and netropsin (Net), which bind to
the minor groove of DNA, can interfere with gene expres-
sion through sequence-speciﬁc recognition of DNA [2–18]
(Figure 1). Baraldi et al. reported on the design, synthesis,
and biological activity of hybrid compounds comprising a
combination of Dst and uramustine (uracil mustard) [14].
Uramustine interacts with GC-rich regions and can alkylate
guanine-N7. The hybrid compounds exhibited enhanced
antitumor activity against the K562 Human Leukemia Cell
Line compared to both distamycin A and uramustine
derivatives. In this case, the interaction with DNA tends to
be dominated by minor groove binding of the Dst moiety.
Given these ﬁndings, we expected that nucleosides bearing
a minor groove binder (MGB) such as a pyrrolepolyamide,
which possesses high aﬃnity for the AAATT sequence,
might be able to regulate gene expression. When the MGB
polyamide-nucleoside hybrid acts on dsDNA, it is expected
that complex formation would involve high aﬃnity and
sequence selectivity through minor groove-binding of the
polyamide moiety and interactions between dsDNA and the
nucleoside moiety of the hybrid such as those involving
Hoogsteen-type hydrogen bonding. On the other hand,
if assuming the hybrid is incorporated into DNA during
DNA biosynthesis, it is expected that DNA replication and
transcription would be obstructed through minor groove-
binding of the hybrid polyamide moiety, incorporated near
the target sequence of the DNA. Therefore, it is preferable
that the pyrrolepolyamide be combined with the nucleoside
site located on the minor groove side of a DNA duplex,
for example, the 2 -position of the sugar moiety and the
2-exocyclic amino group of the guanine base. With this
in mind, we previously designed and synthesized Hybrid
1, where the pyrrolepolyamide is linked at the 2  hydroxyl
group of adenosine, as a lead compound for potential use as2 Journal of Nucleic Acids
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Figure 1: Structures of Distamycin A, Netropsin, Hybrid 1,H y b r i d2, and Hybrid 3.
a new gene therapy agent [19, 20]. Evaluation of the DNA-
binding activity of Hybrid 1 by circular dichroism (CD)
spectralandTm valueanalysesshowedthatalthoughtheΔTm
value (ca.2 ◦C, Table 1) was small, Hybrid 1 displayed greater
binding speciﬁcity than Dst and Net.
On the basis of these results, and for the purpose
of developing a gene control agent through interaction
with the DNA duplex and/or incorporation into DNA
during DNA biosynthesis, we designed MGB polyamide-
2 -deoxynucleoside hybrids, such as Hybrid 2 and Hybrid
3 combined with a pyrrolepolyamide using a linker at the
2-exocyclic amino group of the guanine base (Figure 1).
When considering a DNA strand with incorporated hybrid
during DNA biosynthesis, it is expected that a short linker
might result in high stabilization of the dsDNA. Therefore,
we designed Hybrid 2 containing a 3-aminopropionyl linker
used to the head-to-tail hairpin polyamide reported by
Mrksich et al. [21]. Moreover, for investigations concerning
the stabilization of dsDNA with the complementary strand,
we designed Hybrid 3 containing an alkyl linker connectedJournal of Nucleic Acids 3
directly at the 2-exocyclic amino group of the guanine base.
Here we report on the synthesis and interaction of these
hybrids on DNA duplexes.
2.MaterialsandMethods
2.1. General. Column chromatography was performed on
silica gel (Silica gel N60, purchased from Kanto Chemical
Co., Inc.) using methanol/chloroform as solvent systems.
Melting points were determined using a Yanaco Micro-
melting-pointapparatusandareuncorrected. 1H-N.m.r.and
31P-n.m.r. spectra were recorded on a Bruker DRX 400
apparatus. 19F-N.m.r. spectra were recorded on a Varian
MERCURY 300 apparatus. Mass spectra were recorded on a
Micromass Q-Tof Ultima API apparatus. Elemental analyses
wereachievedusinganElementalVavioELapparatus.Circu-
lar dichroism (CD) spectra were recorded on a JASCO J-720
spectropolarimeter. UV melting curves were measured using
a Shimazu TMSPC-8/UV-1600 apparatus. DNA oligonu-
cleotideswerepurchasedfromHokkaidoSystemScienceCo.,
Ltd. Methyl 4-nitropyrrole-2-carboxylate (5)a n d4 - [ ( tert-
butoxycarbonyl)amino]-1-methylpyrrole-2-carboxylic acid
(6) were prepared according to the procedure described
by Baird and Dervan [3]. 3 ,5 -O-(Tetraisopropyldisiloxane-
1,3-diyl)-2 -deoxyguanosine (12)a n d3  ,5 -di-O-acetyl-
2-ﬂuoro-O6-[2-(4-nitrophenyl)ethyl]-2 -deoxyinosine (20)
were prepared from 2 -deoxyguanosine, as previously
described [22–26].
2.2. Methyl 4-[[4-(Tert-butoxycarbonyl)amino-1-methylpyr-
rol-2-yl]carbonyl]amino-1-methylpyrrole-2-carboxylate (7).
Compound 5 (3.000g, 16.3mmol) was dissolved in ethyl
acetate (100mL) and 10% Pd/C catalyst (1.000g) was
added to the solution. The mixture was stirred under a
slight positive pressure of hydrogen for 12 hours at room
temperature. The catalyst was removed by ﬁltration through
Celite and the ﬁltrate was concentrated in vacuo to give
methyl 4-amino-1-methylpyrrole-2-carboxylate, which was
subsequently used without puriﬁcation. Methyl 4-amino-1-
methylpyrrole-2-carboxylatewasdissolvedinDMF(100mL)
and 4-[(tert-butoxycarbonyl)amino]-1-methylpyrrole-2-ca-
rboxylic acid (6) (3.920g, 16.3mmol), EDCI (6.250g,
32.6mmol) and DMAP (3.980g, 32.6mmol) were added
to the solution. After stirring for 3 hours, the solution was
diluted with ethyl acetate (200mL) and methanol (20mL)
and washed with 3M HCl aq. (100mL×3), H2O (100mL),
5% NaHCO3 aq. (100mL×2) and H2O (100mL). The
organic layer was dried over anhydrous magnesium sulfate
and evaporated to dryness. Compound 7 was obtained in
99% yield (6.070g) as a yellow glass; 1H-n.m.r. (DMSO-d6)
δ 9.85 (s, 1H, -NHCO-), 9.09 (s, 1H, Boc-NH), 7.45 (d, 1H,
J = 1.9Hz, Py-H), 6.90 (d, 1H, J = 1.9Hz, Py-H), 6.89
(s, 1H, Py-H), 6.84 (s, 1H, Py-H), 3.83 (s, 3H, Py-CH3),
3.81 (s, 3H, Py-CH3), 3.73 (s, 3H, -OCH3), 1.45 (s, 9H,
-CH3 of the Boc group); 13C-n.m.r. (DMSO-d6) δ 160.80,
158.42, 152.85, 122.98, 122.60, 122.42, 120.72, 118.49,
117.15, 108.37, 103.82, 78.30, 50.90, 36.13, 36.01, 28.19;
ESI-TOF MS calcd for C18H25N4O5 (M+H)+ 377.1825,
found 377.1826; Anal. Calcd for C18H24N4O5 +0.5H 2O: C,
56.09; H, 6.54; N, 14.54, found C, 56.18; H, 6.28; N, 14.51.
2.3. Methyl 4-[[4-[[4-(Tert-butoxycarbonyl)amino-1-methyl-
pyrrol-2-yl]carbonyl]amino-1-methylpyrrol-2-yl]carbonyl]
amino-1-methylpyrrole-2-carboxylate (8). Compound 7
(3.000g, 16.3mmol) was dissolved in ethyl acetate
(20mL)/methanol (4mL) and acetyl chloride (5.7mL,
80mmol) was added to the solution at 0◦C. The mixture
was stirred for 30 minutes. The reaction solution was
concentrated in vacuo to give methyl 4-[(4-amino-1-meth-
ylpyrrol-2-yl)carbonyl]amino-1-methylpyrrole-2-carboxy-
late, which was subsequently used without puriﬁcation.
Methyl 4-[(4-amino-1-methylpyrrol-2-yl)carbonyl]amino-
1-methylpyrrole-2-carboxylate was dissolved in DMF
(50mL) and 4-[(tert -butoxycarbonyl)amino]-1-methyl-
pyrrole-2-carboxylic acid (6) (2.110g, 8.77mmol), EDCI
(3.060g, 15.9mmol) and DMAP (2.920g, 23.9mmol) were
added to the solution. After stirring for 3 hours, the solution
was diluted with ethyl acetate (200mL)/methanol (20mL)
and washed with 3M HCl aq. (100mL×3), H2O (100mL),
5% NaHCO3 aq. (100mL×2) and H2O (100mL). The
organic layer was dried over anhydrous magnesium sulfate
and evaporated to dryness. Compound 8 was obtained in
98% yield (3.900g); 1H-n.m.r. (DMSO-d6) δ 9.92 (s, 1H,
-NHCO-), 9.87 (s, 1H, -NHCO-), 9.08 (s, 1H, Boc-NH),
7.47 (d, 1H, J = 1.9Hz, Py-H), 7.22 (d, 1H, J = 1.6Hz, Py-
H), 7.08 (d, 1H, J = 1.6Hz, Py-H), 6.92 (d, 1H, J = 1.9Hz,
Py-H), 6.90 (s, 1H, Py-H), 6.85 (s, 1H, Py-H), 3.85 (s,
3H, Py-CH3), 3.84 (s, 3H, Py-CH3), 3.82 (s, 3H, Py-CH3),
3.74 (s, 3H, -OCH3), 1.46 (s, 9H, -CH3 of the Boc group);
13C-n.m.r. (DMSO-d6) δ 160.81, 158.52, 158.44, 152.88,
123.01, 122.83, 122.52, 122.34, 120.74, 118.52, 117.08,
108.38, 104.83, 103.85, 78.29, 50.91, 36.15, 36.04, 28.20.
2.4. 4-[[4-[[4-(Tert-butoxycarbonyl)amino-1-methylpyrrol-2-
yl]carbonyl]amino-1-methylpyrrol-2-yl]carbonyl]amino-
1-methylpyrrole-2-carboxylicacid(9). Compound8(0.249g,
0.5mmol) was dissolved in methanol (2.5mL) and 2M
NaOH aq. (2.5mL) was added to the solution. The mixture
was stirred at 60◦Cf o r1h o u r .T h er e a c t i o ns o l u t i o nw a s
concentrated in vacuo and diluted with H2O( 2 5 m L ) ,
washed with diethyl ether (10mL×3), and neutralized with
10% HCl aq. to ca.p H2 .C o m p o u n d9 was extracted with
ethyl acetate (20mL×3) from the resulting solution. The
organic layer was washed with H2O (30mL), dried over
anhydrous magnesium sulfate and evaporated to dryness.
Compound 9 was obtained in 95% yield (0.230g) as a white
powder; m.p. 175–178◦C; 1H-n.m.r. (DMSO-d6) δ 12.13 (s,
1H, -COOH), 9.88 (s, 1H, -NHCO-), 9.85 (s, 1H, -NHCO-),
9.08 (s, 1H, Boc-NH), 7.42 (d, 1H, J = 1.9Hz, Py-H), 7.21
(d, 1H, J = 1.6Hz, Py-H), 7.07 (d, 1H, J = 1.6Hz, Py-H),
6.89 (s, 1H, Py-H), 6.85 (d, 1H, J = 1.9Hz, Py-H), 6.84 (s,
1H, Py-H), 3.84 (s, 3H, Py-CH3), 3.83 (s, 3H, Py-CH3), 3.81
(s, 3H, Py-CH3), 1.46 (s, 9H, -CH3 of the Boc group); 13C-
n.m.r. (DMSO-d6) δ 161.95, 158.45,158.42, 152.86, 122.81,4 Journal of Nucleic Acids
122.70, 122.57, 122.32, 122.28, 120.25, 119.50, 118.44,
117.06, 108.39, 104.77, 103.82, 48.59, 36.11, 36.02, 28.20;
ESI-TOF MS calcd for C23H29N6O6 (M+H)+ 485.2149,
found 485.2152; Anal. Calcd for C23H28N6O6 +H 2O: C,
54.97; H, 6.02; N, 16.72, found C, 55.18; H, 6.22; N, 16.06.
2.5. 4-[[4-[(4-Formylamino-1-methylpyrrol-2-yl)carbonyl]
amino-1-methylpyrrol-2-yl]carbonyl]amino-1-methylpyrrole-
2-carboxylic acid (10). Compound 9 (77mg, 0.19mmol)
was dissolved in methanol (3mL) and acetyl chloride
(0.85mL, 12mmol) was added to the solution at 0◦C.
After stirring for 30 minutes, the reaction solution was
concentrated in vacuo to dryness. The residue was dissolved
in methanol (1mL) and N-formylimidazole, prepared by
the treatment of formic acid (12.9μL, 0.34mmol) with
1,1 -carbonyldiimidazole (CDI) (36mg, 0.22mmol) in
THF (1.5mL) at room temperature for 5 minutes [11], was
added to the solution at −40◦C. After stirring at −40◦C
for 30 minutes, the solution was diluted with 5% NaHCO3
aq. (10mL), washed with ethyl acetate (10mL × 2), and
neutralized with 10% HCl aq. to ca.p H2 .C o m p o u n d
10 was extracted with ethyl acetate (20mL×3) from the
resulting solution. The organic layer was washed with H2O
(30mL), dried over anhydrous magnesium sulfate, and
evaporated to dryness. The residue was subjected to silica
gel column chromatography using a methanol/chloroform
(1 : 9, v/v) solvent system. Compound 10 was obtained
in 57% yield (45mg) as a white powder; m.p. 178–181◦C;
1H-n.m.r. (DMSO-d6) δ 12.17 (br, 1H, -COOH), 10.05 (d,
1H, J = 1.6Hz, -NHCHO), 9.92 (s, 1H, -NHCO-), 9.89 (s,
1H, -NHCO-), 8.13 (s, 1H, J = 1.6Hz, -CHO), 7.42 (d, 1H,
J = 1.7Hz, Py-H), 7.23 (d, 1H, J = 1.7Hz, Py-H), 7.20 (d,
1H, J = 1.7Hz, Py-H), 7.06 (d, 1H, J = 1.7Hz, Py-H), 6.92
(d, 1H, J = 1.7Hz, Py-H), 6.85 (d, 1H, J = 1.7Hz, Py-H),
3.85 (s, 3H, Py-CH3), 3.84 (s, 3H, Py-CH3), 3.38 (s, 3H,
Py-CH3); 13C-n.m.r. (DMSO-d6) δ 162.70, 162.13, 158.45,
158.31, 157.91, 122.98, 122.67, 122.65, 122.17, 120.76,
120.16, 119.75, 118.51, 118.44, 108.34, 104.74, 103.98,
36.13, 36.06; ESI-TOF MS calcd for C19H21N6O5 (M+H)+
413.1573, found 413.1579.
2.6. 3-[[4-[[4-[(4-Formylamino-1-methylpyrrol-2-yl)carbon-
yl] amino-1-methylpyrrol-2-yl]carbonyl]amino-1-methylpyr-
rol-2-yl]carboxyl]aminopropionic acid (11). Compound 9
(0.100g, 0.206mmol) was dissolved in DMF (2mL) and
ethyl β-alanine hydrochloride (35mg, 0.227mmol), EDCI
(47mg, 0.247mmol), and DMAP (60mg, 0.494mmol)
were added to the solution. After stirring for 3 hours,
the solution was diluted with ethyl acetate (20mL) and
washed with 10% HCl aq. (10mL×3), H2O( 1 0 m L ) ,
5% NaHCO3 aq. (10mL×3), and H2O( 1 0 m L ) .T h e
organic layer was dried over anhydrous magnesium
sulfate and evaporated to dryness. Ethyl 3-[4-[[4-[[4-
(tert-butoxycarbonyl)amino-1-methylpyrrol-2-yl]carbonyl]
amino-1-methylpyrrol-2-yl]carbonyl]amino-1-methylpyrr-
ol-2-yl]carboxyl]aminopropionate was obtained in 85%
yield (102mg); 1H-n.m.r. (DMSO-d6) δ 9.87 (s, 1H,
-NHCO-), 9.85 (s, 1H, -NHCO-), 9.07 (s, 1H, Boc-NH),
8.03 (t, 1H, J = 6Hz, Py-NH), 7.21 (d, 1H, J = 1.3Hz, Py-
H), 7.18 (d, 1H, J = 1.5Hz, Py-H), 7.03 (d, 1H, J = 1.3Hz,
Py-H), 6.89 (s, 1H, Py-H), 6.85 (d, 1H, J = 1.5Hz, Py-H),
6.84 (s, 1H, Py-H), 4.07 (q, 2H, J = 7.1Hz, CH3CH2-), 3.84
(s, 3H, Py-CH3), 3.81 (s, 3H, Py-CH3), 3.80 (s, 3H, Py-CH3),
3.40 (dt, 2H, J = 7HzandJ = 6Hz, -CH2NH-), 2.53 (t, 2H,
J = 7Hz, -COCH2-), 1.46 (s, 9H, -CH3 of the Boc group),
1.19 (t, 3H, J = 7.1Hz, CH3CH2-); 13C-n.m.r. (DMSO-d6)
δ 171.34, 161.27, 158.45, 158.40, 152.84, 122.82, 122.71,
122.65, 122.28, 122.16, 118.35, 117.90, 117.00, 104.27,
103.81, 59.84, 36.00, 35.89, 34.78, 34.02, 28.19, 14.06;
ESI-TOF MS calcd for C28H38N7O7 (M+H)+ 584.2833,
found 584.2822.
Ethyl 3-[4-[[4-[[4-(tert-butoxycarbonyl)amino-1-meth-
ylpyrrol-2-yl]carbonyl]amino-1-methylpyrrol-2-yl]carbon-
yl]amino-1-methylpyrrol-2-yl]carboxyl]aminopropionate
(71.8mg, 0.123mmol) was dissolved in methanol (1mL),
2M NaOH aq. (1mL) was added and the solution was
stirred at 60◦C for 3 hours. The reaction solution was
concentrated in vacuo and diluted with H2O( 1 0 m L ) ,
washed with diethyl ether (5mL×3), and neutralized with
10% HCl aq. to ca. pH 2. The product was extracted with
ethyl acetate (10mL×3) from the resulting solution. The
organic layer was washed with H2O (15mL), dried over
anhydrous magnesium sulfate, and evaporated to dryness.
3-[4-[[4-[[4-(tert-Butoxycarbonyl)amino-1-methylpyrrol-
2-yl]carbonyl]amino-1-methylpyrrol-2-yl]carbonyl]amino-
1-methylpyrrol-2-yl]carboxyl]aminopropionic acid was
obtained in 74% yield (50.2mg); 1H-n.m.r. (DMSO-d6) δ
11.90 (br, 1H, -COOH), 9.87 (s, 1H, -NHCO-), 9.85 (s, 1H,
-NHCO-), 9.07 (s, 1H, Boc-NH), 8.02 (t, 1H, J = 6Hz,
Py-NH), 7.22 (d, 1H, J = 1.6Hz, Py-H), 7.18 (d, 1H,
J = 1.7Hz, Py-H), 7.03 (d, 1H, J = 1.6Hz, Py-H), 6.89
(s, 1H, Py-H), 6.85 (d, 1H, J = 1.7Hz, Py-H), 6.84 (s, 1H,
Py-H), 3.84 (s, 3H, Py-CH3), 3.81 (s, 3H, Py-CH3), 3.80
(s, 3H, Py-CH3), 3.37 (dt, 2H, J = 7Hz and J = 6Hz,
-CH2NH-), 2.45 (t, 2H, J = 7Hz, -COCH2-), 1.46 (s, 9H,
-CH3 of the Boc group); 13C-n.m.r. (DMSO-d6) δ 173.05,
162.31, 158.45, 153.71, 122.84, 122.71, 122.68, 122.28,
122.15, 118.24, 117.85, 116.97, 104.67, 104.28, 103.94, 78.24,
59.74, 36.00, 35.91, 34.89, 34.17, 28.19; ESI-TOF MS calcd
for C26H34N7O7 (M+H)+ 556.2520, found 556.2493.
3-[4-[[4-[[4-(tert-Butoxycarbonyl)amino-1-methylpyrr-
ol-2-yl]carbonyl]amino-1-methylpyrrol-2-yl]carbonyl]ami-
no-1-methylpyrrol-2-yl]carboxyl]aminopropionic acid (40.6
mg, 0.073mmol) was dissolved in methanol (3mL) and
acetyl chloride (0.85mL, 80mmol) was added dropwise
at 0◦C. After stirring for 30 minutes, the solution was
concentrated in vacuo to dryness. The residue was
dissolved in methanol (0.5mL) and to this was added
N-formylimidazole, prepared by the treatment of formic
acid (3.3μL, 0.088mmol) with 1,1 -carbonyldiimidazole
(14.2mg, 0.088mmol) in THF (1mL) at room temperature
for 30 minutes [11], at −40◦C. After stirring at −40◦C
for 1 hour, the solution was diluted with ethyl acetate
(10mL), and washed with sat. NH4Cl aq. (5mL×3) and
H2O (5mL). The organic layer was dried over anhydrous
magnesium sulfate and evaporated to dryness. The residue
was subjected to silica gel column chromatography using aJournal of Nucleic Acids 5
methanol/chloroform (1 : 9, v/v) solvent system. Compound
11 was obtained in 85% yield (30.2mg); 1H-n.m.r. (DMSO-
d6) δ 12.00 (br, 1H, -COOH), 10.03 (d, 1H, J = 1.7Hz,
-NHCHO), 9.91 (s, 1H, -NHCO-), 9.88 (s, 1H, -NHCO-),
8.13 (d, 1H, J = 1.7Hz, -NHCHO), 8.00 (t, 1H, J = 6Hz,
Py-NH), 7.23 (d, 1H, J = 1.7Hz, Py-H), 7.19 (d, 1H,
J = 1.7Hz, Py-H), 7.18 (d, 1H, J = 1.7Hz, Py-H), 7.03 (d,
1H, J = 1.8Hz, Py-H), 6.91 (d, 1H, J = 1.8Hz, Py-H), 6.85
(d, 1H, J = 1.7Hz, Py-H), 3.84 (s, 3H, Py-CH3), 3.83 (s,
3H, Py-CH3), 3.80 (s, 3H, Py-CH3), 3.37 (dt, 2H, J = 7Hz
and J = 6Hz, -CH2NH-), 2.47 (t, 2H, J = 7Hz, -COCH2-);
13C-n.m.r.(DMSO-d6)δ 173.00,161.24,158.42,158.27,157,
85, 122.95, 122.75, 122.13, 122.04, 120.71, 118.39, 117.87,
104.63, 104.24, 103.93, 36.09, 36.05, 35.91, 34.84, 34.07;
ESI-TOF MS calcd for C22H26N7O6 (M+H)+ 484.1945,
found 484.1950.
2.7. N2-[3-[[4-[[4-[(4-Formylamino-1-methylpyrrol-2-yl)ca-
rbonyl]amino-1-methylpyrrol-2-yl]carbonyl]amino-1-methy-
lpyrrol-2-yl]carboxyl]aminopropionyl]-3 ,5 -O-(tetraisopro-
pyldisiloxane-1,3-diyl)-2 -deoxyguanosine (14). Method (1)
Compound 11 was treated with 3 ,5 -O-(tetraisopro-
pyldisiloxane-1,3-diyl)-2 -deoxyguanosine (12) in the pres-
ence of EDCI and DMAP or DCC and HOBT as described
for the syntheses of 7 and 18. The coupling reaction
did not progress and the desired product 14 was not
obtained.
Method (2) N-(9-Fluorenylmethoxycarbonyl)-β-alanine
(4.580g, 14.7mmol) was dissolved in DMF (0.25mL)/THF
(25mL) and oxalyl chloride (1.8mL, 20mmol) was added
to the solution at 0◦C. After stirring for 30 minutes at
room temperature, the solution was concentrated in vacuo
to give 3-[(9-ﬂuorenylmethoxycarbonyl)amino]propionyl
chloride. The residue was dissolved in THF (10mL) and
added to a solution of 3 ,5 -O-(tetraisopropyldisiloxane-
1,3-diyl)-2 -deoxyguanosine (12) in pyridine (80mL).
A f t e rs t i r r i n gf o r7 2h o u r sa tr o o mt e m p e r a t u r e ,H 2O
(10mL) was added to the solution. The solution was
diluted with ethyl acetate (300mL) and washed with H2O
(100mL×3), 5% NaHCO3 aq. (100mL×3), and H2O
(100mL). The organic layer was dried over anhydrous
magnesium sulfate and evaporated to dryness. The residue
was recrystallized from ethyl acetate. The resulting white
crystals were collected by vacuum ﬁltration to give N2-[(9-
ﬂuorenylmethoxycarbonyl)amino]propionyl-3 ,5 -O-(tetra-
isopropyldisiloxane-1,3-diyl)-2 -deoxyguanosine (13)i n
43% yield (3.420g); m.p. 199-200◦C; 1H-n.m.r. (DMSO-d6)
δ 12.02 (br, 1H, N2-H), 11.76 (br, 1H, N1-H), 8.13 (s, 1H,
H-8), 7.85 (d, 2H, J = 7.5Hz, Ar-H of the Fmoc group),
7.66 (dd, 2H, J = 2.6Hz, J = 7.3Hz, Ar-H of the Fmoc
group), 7.42 (t, 1H, J = 6Hz, -CH2NH-Fmoc), 7.37 (t, 1H,
J = 7.5Hz, Ar-H of the Fmoc group), 7.30 (m, 2H, Ar-H of
the Fmoc group), 6.12 (m, 1H, H-1 ), 4.66 (m, 1H, H-3 ),
4.29 (d, 2H, J = 6.7Hz, =CH-CH2- of the Fmoc group),
4.21 (t, 1H, J = 6.7Hz, =CH-CH2- of the Fmoc group),
3.82–3.92 (m, 3H, H-4 ,5  ,a n d5   ), 3.32 (dt, 2H, J = 6Hz,
J = 6,4Hz, -CH2CH2NH-Fmoc), 2.64 (m, 1H, H-2 ), 2.54
(t, 2H, J = 6,4Hz, -COCH2CH2-), 2.50 (m, 1H, H-2  ),
1.01 (m, 28H, -CH(CH3)2 of the TIPDS group); 13C-n.m.r.
(DMSO-d6) δ 174.39, 156.02, 154.78, 148.06, 147.87, 143.82,
140.68, 136.68, 136.73, 127.50, 126.96, 125.07, 120.29,
120.01, 84.64, 81.37, 70.57, 65.36, 61.99, 46.67, 36.50, 36.26,
17.29, 17.23, 17.02, 16.84, 16.76, 12.66, 12.51, 12.17, 11.94;
ESI-TOF MS calcd for C40H55N6O8Si2 (M+H)+ 803.3620,
found 803.3674; Anal. Calcd for C40H54N6O8Si2 +H 2O:
C, 58.51; H, 6.87; N, 10.24, found C, 58.67; H, 6.91;
N,10.43.
Compounds 10 (214mg, 0.27mmol) and 13 (100mg,
0.24mmol)weredissolvedinDMF(5mL)andEDCI(93mg,
0.48mmol) and DMAP (150mg, 1.23mmol) were added
to the solution. After stirring for 24 hours, the solution
was diluted with ethyl acetate (50mL)/methanol (3mL)
and washed with H2O( 3 0 m L ×3). The organic layer was
dried over anhydrous magnesium sulfate and evaporated
to dryness. The residue was subjected to silica gel column
chromatography using a methanol/chloroform (1 : 9, v/v)
solvent system to give 14 (195mg, 83% yield); 1H-n.m.r.
(DMSO-d6) δ 12.05 (br, 1H, N2-H), 11.79 (br, 1H, N1-H),
10.04 (s, 1H, -NHCHO), 9.90 (s, 1H, -NHCO-), 9.88 (s, 1H,
-NHCO-),8.13(s,1H,H-8),8.13(s,1H,-CHO),8.11(t,1H,
J = 5.7Hz, -CH2NHCO-), 7.22 (d, 1H, J = 1.6Hz, Py-H),
7.20 (m, 2H, Py-H × 2), 7.03 (d, 1H, J = 1.7Hz, Py-H), 6.91
(d, 1H, J = 1.8Hz, Py-H), 6.86 (d, 1H, J = 1.6Hz, Py-H),
6.15 (dd, 1H, J = 3.5Hz, J = 7.1Hz, H-1 ), 4.66 (dt, 1H,
J = 7Hz, J = 7.4Hz, H-3 ), 3.83–3.93 (m, 3H, H-4 ,5  ,a n d
5  ), 3.84 (s, 6H, Py-CH3× 2), 3.79 (s, 3H, Py-CH3), 3.50 (dt,
2H, J = 6Hz, J = 6.4Hz, -CH2CH2NH-), 2.75 (m, 2H, H-2 
and 2  ), 2.70 (t, 2H, J = 6,4Hz, -COCH2CH2-), 1.01 (m,
28H, -CH(CH3)2 of the TIPDS group); 13C-n.m.r. (DMSO-
d6) δ 174.77, 161.36, 158.43, 158.28, 157.85, 154.83, 148.14,
148.01, 136.76, 122.96, 122.74, 122.65, 122.19, 122.07,
120.73, 120.27, 118.41, 117.97, 104.65, 104.34, 103.94, 84.63,
81.37, 70.55, 61.96, 36.59, 36.10, 36.06, 35.91, 34.63, 17.32,
17.16, 17.05, 16.87, 16.80, 12.67, 12.52, 12.18, 11.96; ESI-
TOF MS calcd for C44H63N12O10Si2 (M+H)+ 975.4329,
found 975.4271.
2.8. N2-[3-[[4-[[4-[(4-Formylamino-1-methylpyrrol-2-yl)ca-
rbonyl]amino-1-methylpyrrol-2-yl]carbonyl]amino-1-meth-
ylpyrrol-2-yl]carboxyl]aminopropionyl]-2 -deoxyguanosine
(Hybrid 2). Compound 14 (50mg, 0.051mmol) was treated
with 0.2M tetraethylammonium ﬂuoride in THF (3mL)
and stirred at room temperature for 30 minutes. The
solution was concentrated in vacuo to dryness and the
residue was subjected to silica gel column chromatography
using a methanol/chloroform (1 : 4, v/v) solvent system
to give Hybrid 2 (37.3mg, quantitative yield); 1H-n.m.r.
(DMSO-d6) δ 12.04 (br, 1H, N2-H), 11.74 (br, 1H, N1-H),
10.03 (s, 1H, -NHCHO), 9.90 (s, 1H, -NHCO-), 9.88 (s, 1H,
-NHCO-),8.23(s,1H,H-8),8.13(s,1H,-CHO),8.11(t,1H,
J = 5.5Hz, -CH2NHCO-), 7.22 (d, 1H, J = 1.6Hz, Py-H),
7.20 (m, 2H, Py-H×2), 7.02 (d, 1H, J = 1.7Hz, Py-H), 6.91
(d, 1H, J = 1.7Hz, Py-H), 6.85 (d, 1H, J = 1.6Hz, Py-H),
6.20 (t, 1H, J = 6.7Hz, H-1 ), 5.28 (br, 1H, 5 -OH), 4.66
(t, 1H, J = 5.4Hz, H-3 ), 4.36 (br, 1H, 3 -OH), 3.84 (s, 6H,
Py-CH3 ×2), 3.82 (m, 1H, H-4 ),3.79 (s, 3H, Py-CH3), 3.546 Journal of Nucleic Acids
(m, 2H, H-5 ,a n d5   ), 3.50 (dt, 2H, J = 5.5Hz, J = 6.5Hz,
-CH2CH2NH-), 2.71 (t, 2H, J = 6,5Hz, -COCH2CH2-)
2.28 (m, 2H, H-2  and 2  ); 13C-n.m.r. (DMSO-d6) δ 174.74,
161.35, 158.41, 158.27, 157.85, 154.83, 148.35, 147.87,
137.45, 122.95, 122.73, 122.65, 122.16, 122.04, 120.71,
120.18, 118.37, 117.96, 104.64, 104.33, 103.94, 87.72, 82.95,
70.45, 61.46, 36.58, 36.08, 36.05, 35.89, 34.63; ESI-TOF MS
calcdforC32H37N12O10 (M+H)+ 733.2806,found733.2841;
Anal. Calcd for C32H36N12O9 +4H 2O: C, 47.76; H, 5.51; N,
20.89, found C, 47.79; H, 5.84; N, 21.26.
2.9. 9-Fluorenylmethyl 3-aminopropyl-1-carbamate hydro-
chloride (17). 9-Fluorenylmethyl chloroformate (15) (5.174
g, 20mmol) was dissolved in 1,4-dioxane (50mL), and
sodium phenoxide 3 H2O (3.573g, 21mmol) was added to
the solution. After stirring for 1.5 hours at room tempera-
ture,thesolution wasconcentrated invacuoandethylacetate
(100mL) was added. The solution was washed with H2O
(50mL×2) and sat. NaOH aq. (50mL). The organic layer
wasdriedoveranhydrousmagnesiumsulfateandevaporated
to dryness. The residue was subjected to crystallization
from ethyl acetate, collected by vacuum ﬁltration, and dried
in vacuo to yield 9-ﬂuorenylmethyl phenyl carbonate (16)
(5.825g, 92% yield) as a white solid, m.p. 132-133◦C; 1H-
n.m.r. (DMSO-d6) δ 7.92 (d, 2H, J = 7.5Hz, Ar-H of
the Fmoc group×2), 7.68 (d, 2H, J = 7.5Hz, Ar-H of
the Fmoc group×2), 7.15–7.46 (m, 9H, Ph-H×5a n dA r -
H of the Fmoc group×4), 4.68 (d, 2H, J = 6.1Hz,
=CH-CH2- of the Fmoc group), 4.39 (t,1H, J = 6.1Hz,
=CH-CH2- of the Fmoc group); 13C-n.m.r. (DMSO-d6)
δ 152.87, 150.61, 143.15, 140.84, 129.57, 127.78, 127.18,
126.13, 124.94, 121.11, 120.22, 69.38, 46.28; ESI-TOF MS
calcd for C21H16O3 (M+Na)+ 339.0997, found 339.0986;
Anal. Calcd for C21H16O3: C, 79.73; H, 5.10, found C, 79.79;
H, 5.11.
9-Fluorenylmethyl phenyl carbonate (16) (3.763g,
12mmol) was suspended in methanol (50mL) and
propane-1,3-diamine (1.0mL, 12mmol) was added to the
solution. After stirring for 4 hours at room temperature,
pyridinium hydrochloride (3.005g, 26mmol) was added
and the solution stirred for 10 minutes. The solution was
concentrated in vacuo and the residue was subjected to silica
gel column chromatography using a methanol/chloroform
(1 : 4, v/v) solvent system to give 17 (3.250g, 86% yield)
as a white powder; m.p. 129-130◦C; 1H-n.m.r. (DMSO-d6)
δ 7.79 (d, 2H, J = 7.4Hz, Ar-H of the Fmoc group),
7.63 (d, 2H, J = 7.4Hz, Ar-H of the Fmoc group), 7.39
(t, 2H, J = 7.4Hz, Ar-H of the Fmoc group), 7.31 (t,
2H, J = 7.4Hz, Ar-H of the Fmoc group), 4.40 (d, 2H,
J = 6.4Hz, =CH-CH2- of the Fmoc group), 4.20 (t, 1H,
J = 6.4Hz, =CH-CH2- of the Fmoc group), 3.20 (t, 2H,
J = 6.4Hz, -CH2-CH2-CO-), 2.91 (t, 2H, J = 7.3Hz, -CH2-
CH2-N), 1.77–1.83 (m, 2H, -CH2-CH2-CH2-); 13C-n.m.r.
(DMSO-d6) δ159.49, 145.41, 142.80, 128.94, 128.27, 126.21,
121.10, 67.83, 48.64, 38.42, 29.32; ESI-TOF MS calcd for
C18H20N2O2 (M+H)+ 297.1603, found 297.1615; Anal.
Calcd for C18H20N2O2Cl+0.75 H2O: C, 62.42; H, 6.55; N,
8.09, found C, 62.65; H, 6.76: N, 8.61.
2.10. 9-Fluorenylmethyl 3-[4-[[4-[[4-(tert-butoxycarbonyl)
amino-1-methylpyrrol-2-yl]carbonyl]amino-1-methylpyrrol-
2-yl]carbonyl]amino-1-methylpyrrol-2-yl]carboxyl]amino-
propyl-1-carbamate (18). Compounds 10 (50mg,0.1mmol)
and 17 (38mg, 0.11mmol) were dissolved in DMF (3mL)
and dicyclohexylcarbodiimide (26mg, 0.12mmol) and 1-
hydroxybenzotriazole (17mg, 0.12mmol) were added to the
solution.Afterstirringfor24hoursatroomtemperature,the
solution was diluted with ethyl acetate (50mL) and washed
with 3M HCl aq. (25mL×3), H2O (25mL), 5% NaHCO3
aq. (25mL×2), and H2O (25mL). The organic layer was
dried over anhydrous magnesium sulfate, evaporated to
dryness, and the residue was subjected to silica gel column
chromatography using a methanol/chloroform (1 : 49, v/v)
solvent system to give 18 (75.6mg, 96% yield); 1H-n.m.r.
(DMSO-d6) δ 9.87 (s, 1H, -NHCO-), 9.85 (s, 1H, -NHCO-),
9.08 (s, 1H, Boc-NH), 7.95 (t, 1H, J = 5.5Hz, -CH2NHCO-
), 7.88 (d, 2H, J = 7.4Hz, Ar-H of the Fmoc group),
7.69 (d, 2H, J = 7.4Hz, Ar-H of the Fmoc group), 7.41
(t, 2H, J = 7.4Hz, Ar-H of the Fmoc group), 7.32 (t, 2H,
J = 7.4Hz,Ar-HoftheFmocgroup),7.26(t,1H,J = 5.6Hz,
-CH2NH-Fmoc), 7.21 (d, 1H, J = 1.7Hz, Py-H), 7.18 (d,
1H, J = 1.5Hz, Py-H), 7.04 (d, 1H, J = 1.7Hz, Py-H), 6.89
(s, 1H, Py-H), 6.86 (d, 1H, J = 1.5Hz, Py-H), 6.84 (s, 1H,
Py-H), 4.32 (d, 2H, J = 6.6Hz, =CH-CH2- of the Fmoc
group), 4.22 (t, 1H, J = 6.6Hz, =CH-CH2- of the Fmoc
group), 3.84 (s, 3H, Py-CH3), 3.81 (s, 3H, Py-CH3), 3.80 (s,
3H, Py-CH3), 3.17 (m, 2H, -NHCH2CH2-), 3.03 (m, 2H,
-CH2CH2N H - ) ,1 . 6 2( m ,2 H ,- C H 2CH2CH2-), 1.46 (s, 9H,
-CH3 of the Boc group); 13C-n.m.r. (DMSO-d6) δ 161.25,
158.45, 158.41, 156.10, 152.80, 143.91, 140.72, 127.56,
127.02, 125.09, 122.89, 122.82, 122.73, 122.29, 122.15,
120.08, 118.34, 117.77, 117.02, 104.68, 104.49, 103.81, 78.35,
65.19, 46.76, 38.03, 36.00, 35.89, 29.64; ESI-TOF MS calcd
for C41H47N8O7 (M+H)+ 763.3568, found 763.3591; Anal.
Calcd for C41H46N8O7 +2H 2O: C, 61.64; H, 6.31; N, 14.03,
found C, 62.12; H, 6.10; N, 14.09.
2.11.9-Fluorenylmethyl 3-[4-[[4-[(4-Formylamino-1-methyl-
pyrrol-2-yl)carbonyl]amino-1-methylpyrrol-2-yl]carbonyl]
amino-1-methylpyrrol-2-yl]carboxyl]aminopropyl-1-carba-
mate (19). Compound 18 (0.696g, 0.91mmol) was
dissolved in methanol (12mL) and acetyl chloride (3mL,
42mmol) was added to the solution at 0◦C. After stirring
for 30 minutes, the reaction solution was concentrated in
vacuo to dryness. The residue was dissolved in methanol
(5mL)/THF (10mL) and N-formylimidazole, prepared
by the treatment of formic acid (41μL, 1.09mmol) with
1,1 -carbonyldiimidazole (177mg, 1.09mmol) in THF
(4mL) at room temperature for 5 minutes [11], was added
to the solution at −40◦C. After stirring at −40◦Cf o r1h o u r ,
the solution was diluted with 5% NaHCO3 aq. (10mL),
washed with ethyl acetate (10mL×2), and neutralized with
10% HCl aq. to ca.p H2 .C o m p o u n d10 was extracted
with ethyl acetate (20mL×3) from the resulting solution.
The organic layer was washed with H2O (30mL), dried
over anhydrous magnesium sulfate, and evaporated to
dryness. The residue was subjected to silica gel columnJournal of Nucleic Acids 7
chromatography using a methanol/chloroform (1 : 19, v/v)
solvent system. Compound 19 was obtained in 88% yield
(0.555g); 1H-n.m.r. (DMSO-d6) δ 10.04 (d, 1H, J = 1.7Hz,
-NHCHO), 9.91 (s, 1H, -NHCO-), 9.88 (s, 1H, -NHCO-),
8.13 (d, 1H, J = 1.7Hz, -NHCHO), 7.96 (t, 1H, J = 5.6Hz,
-CH2NHCO-), 7.88 (d, 2H, J = 7.4Hz, Ar-H of the Fmoc
group), 7.65 (d, 2H, J = 7.4Hz, Ar-H of the Fmoc group),
7.41(t,2H,J = 7.4Hz,Ar-HoftheFmocgroup),7.33(t,2H,
J = 7.4Hz,Ar-HoftheFmocgroup),7.25(t,1H,J = 5.6Hz,
-CH2NH-Fmoc), 7.23 (d, 1H, J = 1.8Hz, Py-H), 7.20 (d,
1H, J = 1.8Hz, Py-H), 7.19 (d, 1H, J = 1.5Hz, Py-H), 7.04
(d, 1H, J = 1.8Hz, Py-H), 6.92 (d, 1H, J = 1.8Hz, Py-H),
6.87 (d, 1H, J = 1.5Hz, Py-H), 4.32 (d, 2H, J = 6.7Hz,
=CH-CH2- of the Fmoc group), 4.22 (t, 1H, J = 6.7Hz,
=CH-CH2- of the Fmoc group), 3.85 (s, 6H, Py-CH3 ×2),
3.80 (s, 3H, Py-CH3), 3.16 (m, 2H, -NHCH2CH2-), 3.03
(m, 2H, -CH2CH2N H - ) ,1 . 6 1( m ,2 H ,- C H 2CH2CH2-);
13C-n.m.r. (DMSO-d6) δ 161.24, 158.42, 158.27, 157.85,
143.91, 140.72, 128.89, 127.56, 127.03, 125.09, 122.95,
122.76, 122.05, 120.71, 120.08, 118.34, 117.77, 104.63,
104.08, 103.93, 65.19, 46.76, 38.88, 38.03, 36.09, 35.89;
ESI-TOF MS calcd for C37H39N8O6 (M+H)+ 691.2993,
found 691.2974; Anal. Calcd for C37H38N8O6 +H 2O: C,
62.70; H, 5.69; N, 15.81, found C, 63.05; H, 5.69; N, 16.00.
2.12. N2-[3-[[4-[[4-[(4-Formylamino-1-methylpyrrol-2-yl)
carbonyl]amino-1-methylpyrrol-2-yl]carbonyl]amino-1-me-
thylpyrrol-2-yl]carboxyl]aminopropyl]-3 ,5 -di-O-acetyl-O6-
[2-(4-nitrophenyl)ethyl]-2 -deoxyguanosine (21). Compo-
und 19 (150mg. 0.22mmol) was dissolved in 10%
piperidine/DMF (1mL). After stirring at room temperature
for 20 minutes, the solution was concentrated in vacuo
to dryness. The residue and 3 ,5 -di-O-acetyl-2-ﬂuoro-
O6-[2-(4-nitrophenyl)ethyl]-2 -deoxyinosine (20) (0.219g,
0.43mmol)weredissolvedinDMF(2mL)andtriethylamine
(60μL, 0.43mmol) was added to the solution. After stirring
at 60◦C for 12 hours, the reaction solution was concentrated
in vacuo to dryness. The residue was subjected to silica
gel column chromatography using a methanol/chloroform
(1 : 19, v/v) solvent system to give 21 (0.168g, 81%
yield); 1H-n.m.r. (DMSO-d6) δ 10.19 (d, 1H, J = 1.7Hz,
-NHCHO), 9.91 (s, 1H, -NHCO-), 9.87 (s, 1H, -NHCO-),
8.16 (d, 2H, J = 8Hz, Ar-H of the NPE group), 8.13 (d,
1H, J = 1.7Hz, -NHCHO), 8.03 (s, 1H, H-8), 8.01 (t, 1H,
J = 5.4Hz, -CH2NHCO-), 7.60 (d, 2H, J = 8Hz, Ar-H of
the NPE group), 7.22 (d, 1H, J = 1.7Hz, Py-H), 7.19 (d, 1H,
J = 1.8Hz, Py-H), 7.16 (d, 1H, J = 1.7Hz, Py-H), 7.04 (d,
1H, J = 1.7Hz, Py-H), 7.01 (t, 1H, J = 5.7Hz, N2-H), 6.91
(d, 1H, J = 1.9Hz, Py-H), 6.90 (d, 1H, J = 1.3Hz, Py-H),
6.24 (t, 1H, J = 6.7Hz, H-1 ), 5.41 (m, 1H, H-3 ), 4.68 (t,
J = 6.6Hz, -CH2CH2- of the NPE group), 4.31 (m, 1H,
H-4 ), 4.19 (m, 2H, H-5  and 5  ), 3.84 (s, 6H, Py-CH3 ×2),
3.80 (s, 3H, Py-CH3), 3.36 (m, 2H, -NHCH2CH2-), 3.25
(m, 4H, -CH2CH2- of the NPE group and -CH2CH2NH-
), 3.12 (m, 1H, H-2 ), 2.45 (m, 1H, H-2  ), 2.08 (s, 3H,
the Ac group), 1.99 (s, 3H, the Ac group), 1.76 (m, 2H,
-CH2CH2CH2-); 13C-n.m.r. (DMSO-d6) δ 170.10, 169.99,
161.31, 159.99, 158.70, 158.42, 158.28, 157.86, 146.71
146.22, 130.20, 123.38, 122.95, 122.77, 122.16, 120.72,
118.37, 117.72, 104.64, 104.13, 103.94, 81.35, 65.41, 63.64,
36.22, 36.04, 35.89, 34.31, 20.77, 20.47; ESI-TOF MS calcd
for C44H50N13O12 (M+H)+ 952.3702, found 952.3738.
2.13. N2-[3-[[4-[[4-[(4-Formylamino-1-methylpyrrol-2-yl)
carbonyl]amino-1-methylpyrrol-2-yl]carbonyl]amino-1-me-
thylpyrrol-2-yl]carboxyl]aminopropyl]-2  -deoxyguanosine
(Hybrid 3). Compound 21 (0.116g, 0.12mmol) was treated
with 0.5M DBU/pyridine (2mL). After stirring at room
temperature for 12 hours, ammonium chloride (80mg,
1.5mmol) was added to the solution. The solution was
diluted with chloroform (60mL) and washed with H2O
(25mL). The organic layer was dried over anhydrous
magnesium sulfate, evaporated to dryness, and the residue
was subjected to silica gel column chromatography using
a methanol/chloroform (1 : 4, v/v) solvent system to give
N2-[3-[[4-[[4-[(4-formylamino-1-methylpyrrol-2-yl)carbo-
nyl]amino-1-methylpyrrol-2-yl]carbonyl]amino-1-methyl-
pyrrol-2-yl]carboxyl]aminopropyl]-3 ,5 -di-O-acetyl-2 -de-
oxyguanosine (71mg, 73% yield); 1H-n.m.r. (DMSO-d6) δ
10.70 (br, 1H, N1-H), 10.07 (d, 1H, J = 1.5Hz, -NHCHO),
9.91 (s, 1H, -NHCO-), 9.87 (s, 1H, -NHCO-), 8.12 (d,
1H, J = 1.5Hz, -NHCHO), 8.04 (t, 1H, J = 5.8Hz,
-CH2NHCO-), 7.87 (s, 1H, H-8), 7.22 (d, 1H, J = 1.6Hz,
Py-H), 7.19 (d, 1H, J = 1.6Hz, Py-H), 7.17 (d, 1H,
J = 1.6Hz, Py-H), 7.06 (d, 1H, J = 1.7Hz, Py-H), 6.91 (d,
1H, J = 1.7Hz, Py-H), 6.90 (d, 1H, J = 1.6Hz, Py-H), 6.64
(t, 1H, J = 5Hz, N2-H), 6.18 (t, 1H, J = 7Hz, H-1 ), 5.46
(m, 1H, H-3 ), 4.30 (m, 1H, H-4 ), 4.17 (m, 2H, H-5  and
5  ),3.84 (s,6H, Py-CH3 ×2),3.80 (s,3H, Py-CH3),3.35(m,
2H, -NHCH2CH2-), 3.25 (m, 2H, -CH2CH2NH- ), 3.05 (m,
1H, H-2 ), 2.47 (m, 1H, H-2  ), 2.08 (s, 3H, the Ac group),
1.99 (s, 3H, the Ac group), 1.74 (m, 2H, -CH2CH2CH2-);
ESI-TOF MS calcd for C36H43N12O10 (M+H)+ 803.3225,
found 803.3201.
N2-[3-[[4-[[4-[(4-Formylamino-1-methylpyrrol-2-yl)
carbonyl]amino-1-methylpyrrol-2-yl]carbonyl]amino-1-
methylpyrrol-2-yl]carboxyl]aminopropyl]-3 ,5 -di-O-acet-
yl-2 -deoxyguanosine (71.4mg, 0.089mmol) was dis-
solved in pyridine (0.2mL) and 0.05M sodium
methoxide/methanol (0.8mL) was added to the solution.
After stirring at room temperature for 2 hours, the solution
was neutralized with Dowex-50WX2 ion-exchange resin (H+
form) after which time the resin was immediately removed
by ﬁltration. The ﬁltrate was evaporated to dryness and the
residue was crystallized from methanol. The resulting white
crystals were collected by vacuum ﬁltration to give Hybrid 3
(51.1mg, 80% yield); 1H-n.m.r. (DMSO-d6) δ 10.80 (br, 1H,
N1-H), 10.05 (d, 1H, J = 1.6Hz, -NHCHO), 9.91 (s, 1H,
-NHCO-), 9.87 (s, 1H, -NHCO-), 8.12 (m, 2H, -NHCHO
and H-8), 8.07 (t, 1H, J = 5.6Hz, -CH2NHCO-), 7.22 (d,
1H, J = 1.8Hz, Py-H), 7.19 (d, 1H, J = 1.8Hz, Py-H), 7.18
(d, 1H, J = 1.8Hz, Py-H), 7.04 (d, 1H, J = 1.8Hz, Py-H),
6.91 (d, 1H, J = 1.8Hz, Py-H), 6.89 (d, 1H, J = 1.8Hz, Py-
H), 6.62 (br, 1H, N2-H), 6.17 (t, 1H, J = 6.8Hz, H-1 ), 4.36
(m, 1H, H-3 ), 3.84 (s, 3H, Py-CH3), 3.83 (s, 3H, Py-CH3),
3.82 (m, 1H, H-4 ), 3.80 (s, 3H, Py-CH3), 3.56 (m, 1H,8 Journal of Nucleic Acids
H-5 ), 3.50 (m, 1H, H-5  ), 3.33 (m, 2H, -NHCH2CH2-),
3.25 (m, 2H, -CH2CH2NH- ), 2.61 (m, 1H, H-2 ), 2.24
(m, 1H, H-2  ), 1.75 (m, 2H, -CH2CH2CH2-); 13C-n.m.r.
(DMSO-d6) δ 161.43, 158.43, 158.23, 157.85, 156.17, 152.78,
150.19, 135.69, 122.94, 122.88, 122.75, 122.13, 122.05,
120.71, 118.37, 117.82, 104.65, 104.65, 104.23, 103.95,
87.71, 83.16, 70.65, 61.65, 38.21, 36.09, 36.05, 35.90. 29.15;
ESI-TOF MS calcd for C32H39N12O8 (M+H)+ 719.3014,
found 719.3005; Anal. Calcd for C37H38N8O6 +1.5H 2O: C,
51.54; H, 5.54; N, 22.54, found C, 51.36; H, 5.50; N, 22.26.
2.14. Circular Dichroism (CD) Spectroscopy. CD spectra
were measured using a JASCO J-720 spectropolarimeter
equipped with a thermoelectrically controlled cell holder
and a cuvette with a path length of 10mm. CD titrations
were conducted at 20◦C by incrementally injecting 15μL
aliquots of a 270μM ligand (Hybrid 2,H y b r i d3, or Dst)
solution into 3mL of a 5.8μM duplex [DNA 1: d-(5 -
CGCAAATTGGC-3 )-d-(3 -GCGTTTAACCG-5 )], DNA
2: d-(5 -CGCAGACTGGC-3 )-d-(3 -GCGTCTGACCG-
5 )], or DNA 3: d-(5 -GCACGACTACG-3 )-d-(3 -
CGTGCTGATGC-5 )] solution in the same buﬀer [19, 20].
The resulting ligand concentration in the DNA duplex
solution increased from 0 to 18.1μM. After each injection,
the CD spectrum was recorded between 220 and 380nm.
2.15. UV Absorption Spectroscopy. In an eﬀort to assess the
eﬀect of the bound ligand (Hybrid 1,H y b r i d2,H y b r i d3,o r
Dst) on the thermal stability of the three duplexes (DNA 1–
3), UV melting experiments were conducted in the absence
and presence of each ligand. Absorbance versus temperature
proﬁles were measured using a Shimazu TMSPC-8/UV-1600
spectrophotometer equipped with a thermoelectrically con-
trolled cell holder at 260nm and a heating rate of 1.0◦C/min.
The concentration of each 11mer duplex was 4.3μM, while
the ligand concentrations varied from 0 to 12.9μM.
3. Results andDiscussion
Hybrid 2 incorporating the 3-aminopropionyl linker was
synthesized by condensation of N2-(Fmoc-β-alanyl)-3 ,5 -
O-TIPDS-guanosine (12) with pyrrole amide trimer 10 as
shown in Scheme 2.
Pyrrole amide trimer 10 was prepared using modiﬁca-
tions of the method of Baird and Dervan [3]. The monomer
building blocks methyl 4-nitropyrrole-2-carboxylate (5)a n d
4-(tert-butoxycarbonyl)amino-1-methylpyrrole-2-carboxyl-
ic acid (6) were synthesized from N-methylpyrrole via
2-trichloroacetylation, 4-nitration and esteriﬁcation to give
5, and subsequent alkaline hydrolysis of ester 5 to give 6.
Using pyrrole monomers 5 and 6, pyrroleamide trimer 10
was synthesized as shown in Scheme 1. Monomer 5 was
reducedtogivemethyl4-aminopyrrole-2-carboxylate,which
was then coupled with 6 in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDCI)
and 4-(dimethylamino)pyridine (DMAP) to give dimer 7.
Next, following deprotection of the Boc group, dimer 7 was
coupled with 6 to give trimer 8.T r i m e r8 was then converted
to trimer 10 through alkaline hydrolysis of the ester moiety,
deprotection of the Boc group, and ﬁnally N-formylation
[11].
We initially attempted the synthesis of the pyrrole-
polyamide-2 -deoxyguanosine hybrid (Hybrid 2) by
condensation of 3 ,5 -O-TIPDS-guanosine (12)a n dp y r r o l e
amide trimer 11, prepared by coupling pyrrole amide
trimer 9 with ethyl β-alanine, alkaline hydrolysis of the
ester moiety, deprotection of the Boc group, and ﬁnally
N-formylation. The desired compound was not obtained
when using EDCI/DMAP or dicyclohexylcarbodiimide
(DCC)/hydroxybenztriazole (HOBT) as condensation
reagents due to the low reactivity of the exocyclic amino
group of the guanine base. We then attempted the synthesis
of Hybrid 2 using pyrrole amide trimer 10 and N2-[3-
(9-ﬂuorenylmethoxycarbonylamino)propioyl]-3 ,5 -O-
TIPDS-guanosine (13). Compound 13 was prepared by
reaction of 3 ,5 -O-TIPDS-guanosine (12) with 3-(Fmoc-
amino)propionyl chloride, prepared from N-Fmoc-β-
alanine and SOCl2, in 43% yield. Treatment of 13 with
pyrroleamide trimer 10 in the presence of EDCI and
a large excess of DMAP generated pyrrolepolyamide-
2 -deoxyguanosine derivative 14 in 83% yield through
deprotection of the Fmoc group of 13 and condensation
of the amine product with 10.H y b r i d2 was obtained
in quantitative yield from 14 by treatment with 0.2 M
tetraethylammonium ﬂuoride (TEAF) in THF.
Hybrid 3 incorporating the 3-aminopropyl linker
was synthesized using 3 ,5 -di-O-acetyl-2-ﬂuoro-O6-[2-(4-
nitrophenyl)ethyl]-2 -deoxyinosine (20)a n dp y r r o l ea m i d e
trimer 19 as shown in Scheme 4. Monoprotected propane-
1,3-diamine containing the Fmoc group, which can be
deprotected under mild basic conditions and is stable
during deprotection of the Boc group, was designed as the
linker reagent. Monoprotection of propane-1,3-diamine by
treatment with 9-ﬂuorenylmethyl chloroformate (Fmoc-Cl)
under basic conditions in the presence of a large excess of
propane-1,3-diamine and Na2CO3 was initially examined.
The desired compound was not obtained due to the low
selectivity of monoprotection and basic lability of the Fmoc
group. Pittelkov et al. reported on the monoprotection of
alkanediamines[H2N-(CH2)n-NH2:n = 0–4]withBoc,Cbz
or allyloxycarbonyl groups using the corresponding phenyl
carbonates.Monoprotectedalkanediamineswereobtainedin
46%–86% yield [27]. Using a modiﬁcation of the method of
Pittelkov et al., we then treated propane-1,3-diamine with
9-ﬂuorenylmethyl phenyl carbonate (16), prepared from
Fmoc-Cl and sodium phenoxide in 87% yield, and then 1M
HCl aq. to give the HCl salt of 3-(Fmoc-amino)propylamine
as shown in Scheme 3. Linker reagent 17 was obtained in
69% yield. Pyrrole amide trimer 10 was condensed with
linker reagent 17 in the presence of DCC, HOBT, and
diisopropylethylamine (DIEA) in DMF to generate pyrrole
amide trimer 18, obtained in 96% yield. Pyrrole amide
trimer 18 was then subjected to deprotection of the Boc
group and subsequent N-formylation to give pyrrole amide
trimer 19. Treatment of pyrrole amide trimer 19 with
2 -deoxy-2-ﬂuoroinosine derivative 20 in the presence of
triethylamine in DMF at 60◦C for 12 hours generated theJournal of Nucleic Acids 9
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desired pyrrolepolyamide-2 -deoxyguanosine derivative 21
in 81% yield through deprotection of the Fmoc group of 19
and condensation of the amine product with 20. Cleavage
of the NPE protecting group using 0.5 M DBU in pyridine
[28] and subsequent deacetylation using sodium methoxide
in methanol generated Hybrid 3 in good yield.10 Journal of Nucleic Acids
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ForourinvestigationsconcerningtheinteractionofDNA
duplexeswithHybrid2andHybrid3usingCDandUVmelt-
ing data (Tm value) [29], DNA 1 [d-(5 -CGCAAATTGGC-
3 )-d-(3 -GCGTTTAACCG-5 )], which contains the high
aﬃnitybindingsiteofDst,DNA2[d-(5 -CGCAGACTGGC-
3 )-d-(3 -GCGTCTGACCG-5 )], which included changes at
A5toG5andT7toC7,andDN A3[d-(5  -GCACGACTACG-
3 )-d-(3 -CGTGCTGATGC-5 )], which represents a randomJournal of Nucleic Acids 11
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Figure 2: CD spectra for the DNA duplexs with ligand (Hybrid 2,H y b r i d3,D s t ,o rc o m p o u n d11) at several [Iigand]/[duplex] ratios
in buﬀer consisting of 10mM sodium phosphate, 10mM NaCL, and 0.1mM Na2EDTA at pH 7.0 and 20◦C: 3.0mL of duplex solution
(5.8μM) titrated ligand (Hybrid 2, Hybrid 3, and Dst: 0–14.5μM) and 3.0mL of duplex solution (4μM) titrated ligand (compound 11:
0–12μM). ∗DNA duplexs: DNA 1 = d-(5 -CGCAAATTGGC-3 )-d-(3 -GCGTTTAACCG-5 ), DNA 2 = d-(5 -CGCAGACTGGC-3 )-d-(3 -
GCGTCTGACCG-5 ), DNA 3 = d-(5 -GCACGACTACG-3 )-d-(3 -CGTGCTGATGC-5 ), DNA 1 contains the high aﬃnity binding site (5 -
AAATT-3 )o fD s t .
sequence,wereused(Figure 2andTable 1).Moreover,exper-
iments employing Dst and compound 11 were conducted
for comparison. Typical CD spectra of the uncomplexed
DNA duplexes (DNA 1–3), indicative of DNA in the B-form
conformation, are shown in Figure 2 (ligand=0μM). The
addition of Hybrid 2,H y b r i d3, or Dst resulted in marked
changes in the ellipticity θ, unlike the case with compound
11. In particular, an induced Cotton eﬀect of bound ligand
is indicated by the presence of an extra CD band centered
at ∼325nm for Hybrid 2 and Hybrid 3,a n d∼333nm for12 Journal of Nucleic Acids
Table 1: ΔTm values (◦C) for the DNA duplexs with ligand (Hybrid
1,H y b r i d2,H y b r i d3, or Dst) at several [ligand]/[duplex] ratios in
buﬀer consisting of 10mM sodium phosphate, 10mM NaCl, and
0.1mM Na2EDTA at pH 7.0.
[ligand]/[duplex] 1 : 1 2 : 1 3 : 1
DNA 1 2.1 2.3 —
Hybrid 1 DNA 2 − 0.1 0.2 —
DNA 3 −0.4 0.3 —
DNA 1 2.7 3.8 3.9
Hybrid 2 DNA 2 −0.3 −0.2 − 0.1
DNA 3 0.2 0.3 0.3
DNA 1 5.6 5.7 5.8
Hybrid 3 DNA 2 0.1 0.2 0.5
DNA 3 − 0.3 −0.5 −0.2
DNA 1 22.9 22.9 23.5
Dst DNA 2 3.0 6.5 6.9
DNA 3 15.2 16.3 16.3
∗ΔTm value = (Tm value in the presence of ligand)-(Tm value in the absence
of ligand).
∗∗DNA duplexs: DNA 1 = d-(5 -CGCAAATTGGC-3 )-d-(3 -
GCGTTTAACCG-5 ) Tm = 32.2◦C.
DNA 2 = d-(5 -CGCAGACTGGC-3 )-d-(3 -GCGTCTGACCG-5 ) Tm =
39.5◦C.
DNA 3 = d-(5 -GCACGACTACG-3 )-d-(3 -CGTGCTGATGC-5 ) Tm =
33.9◦C.
DNA 1 contains the high aﬃnity binding site (5 -AAATT-3 )o fD s t .
Dst. Hybrid 3 showed selective binding aﬃnity only with
DNA 1, which contains the AAATT sequence (Figure 2),
and stabilization of the DNA duplex (Table 1). On the other
hand, Hybrid 2, combined with a pyrrolepolyamide at the 2-
exocyclic amino group of the guanine base through an amide
bond using a 3-aminopropionyl linker, and Dst containing
the cationic amidine edge which contributes to high DNA
binding aﬃnity forligand binding [30–33],did not show any
marked diﬀerences in sequence-speciﬁc binding aﬃnity with
the tested DNA.
4. Conclusions
We synthesized and evaluated pyrrolepolyamide-2 -
deoxyguanosine hybrids (Hybrid 2 and Hybrid 3)
incorporating 3-aminopropionyl or 3-aminopropyl linkers.
Hybrid 3, combined with a pyrrolepolyamide at the 2-
exocyclic amino group of the guanine base through an
N-alkyl bond using a 3-aminopropyl linker, showed high
recognition of DNA containing the pyrrolepolyamide
binding sequence. These results suggest that improvements
in stability might be eﬀected by varying the length of
the linker. On the other hand, in a DNA strand with
incorporated hybrid during DNA biosynthesis, the presence
ofashortlinker,suchasthe3-aminopropionylmoiety,might
result in high stabilization of the dsDNA. These studies are
currently underway and will be reported elsewhere. The
minor groove binder pyrrolepolyamide-2 -deoxyguanosine
hybrid presented in this report might potentially be of use
as a sequence-speciﬁc gene therapy agent and could provide
the basis for the development of a new series of antisense or
antigene drugs.
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